These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33794589)

  • 1. Sustained complete response on crizotinib in primary lung inflammatory myofibroblastic tumor - Case report and literature review.
    Mittal A; Gupta A; Dhamija E; Barwad A; Rastogi S
    Monaldi Arch Chest Dis; 2021 Mar; 91(3):. PubMed ID: 33794589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
    Schöffski P; Kubickova M; Wozniak A; Blay JY; Strauss SJ; Stacchiotti S; Switaj T; Bücklein V; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Lee CJ; Speetjens FM; Nzokirantevye A; Neven A; Kasper B
    Eur J Cancer; 2021 Oct; 156():12-23. PubMed ID: 34392187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation.
    Ogata M; Hatachi Y; Ogata T; Satake H; Imai Y; Yasui H
    Intern Med; 2019 Apr; 58(7):1029-1032. PubMed ID: 30449794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "How long does crizotinib work? a rare case of recurrent inflammatory myofibroblastic tumor".
    Albayrak HC; Gürler F; Sütçüoğlu O; Akyürek N; Özet A
    Anticancer Drugs; 2022 Jan; 33(1):109-111. PubMed ID: 34261914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizotinib in ALK
    Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T
    Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.
    Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M
    Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.
    Liu W; Duan Q; Gong L; Yang Y; Huang Z; Guo H; Niu X
    Invest New Drugs; 2021 Feb; 39(1):278-282. PubMed ID: 32915420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
    Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
    Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete remission for 4 years with crizotinib in advanced ALK-positive non-small cell lung cancer after thoracostomy for empyema.
    Van Damme E; Kiselinova M; Van Schoote E
    Tumori; 2019 Dec; 105(6):NP35-NP37. PubMed ID: 31023173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.
    Alan O; Kuzhan O; Koca S; Telli TA; Basoglu T; Ercelep O; Filinte D; Sengul Y; Arikan H; Kaya S; Babacan NA; Dane F; Yumuk PF
    J Oncol Pharm Pract; 2020 Jun; 26(4):1011-1018. PubMed ID: 31615346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year crizotinib monotherapy induced durable complete response of pediatric ALK-positive inflammatory myofibroblastic tumor.
    Kaino A; Niizuma H; Katayama S; Irie M; Nakano T; Sato D; Saito T; Kato S; Suehara Y; Sasahara Y; Kikuchi A
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30330. PubMed ID: 37017194
    [No Abstract]   [Full Text] [Related]  

  • 12. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
    Parker BM; Parker JV; Lymperopoulos A; Konda V
    J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib combined with bronchoscopic interventional treatment in ALK-positive inflammatory myofibroblastic tumor of left main stem bronchus: a case report.
    Zhang P; Wang C; Lv Z; Du M; Xu R
    J Cardiothorac Surg; 2023 Nov; 18(1):318. PubMed ID: 37950305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.
    Brivio E; Zwaan CM
    Pediatr Blood Cancer; 2019 May; 66(5):e27645. PubMed ID: 30697903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel
    Pan X; Zhong A; Xing Y; Li X; Du H; Shi M
    J Int Med Res; 2021 Sep; 49(9):3000605211044652. PubMed ID: 34590916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
    Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
    Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
    Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
    Gambacorti-Passerini C; Orlov S; Zhang L; Braiteh F; Huang H; Esaki T; Horibe K; Ahn JS; Beck JT; Edenfield WJ; Shi Y; Taylor M; Tamura K; Van Tine BA; Wu SJ; Paolini J; Selaru P; Kim TM
    Am J Hematol; 2018 May; 93(5):607-614. PubMed ID: 29352732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.